8-K: Jazz Pharma Q1 2026 Results: Revenue Up 19%, Zanidatamab sBLA Priority Review

Jazz Pharmaceuticals announced first quarter 2026 financial results, with total revenues reaching $1.1 billion, a 19% year-over-year increase, driven by strong commercial execution across its franchises.

Summary

• Total revenues for the first quarter of 2026 were $1.1 billion, representing a 19% increase compared to the same period in 2025.
• GAAP net income was $293.1 million, or $4.43 per diluted share, while non-GAAP adjusted net income was $419.5 million, or $6.34 per diluted share.
• Xywav net product sales grew 18% year-over-year to $408 million, with approximately 425 net new patients added.
• Epidiolex/Epidyolex net product sales increased 15% year-over-year to $250 million.
• Zepzelca net product sales increased 60% year-over-year to $101 million.
• The company reaffirmed its full-year 2026 revenue guidance of $4.25 billion to $4.50 billion.
• The FDA granted Priority Review for the zanidatamab sBLA for HER2+ 1L GEA, with a PDUFA date of August 25, 2026.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report, with significant revenue growth, successful product performance, and positive pipeline developments, including a key FDA Priority Review.

Positives

• Total revenues increased by 19% year-over-year to $1.1 billion.
• Strong commercial execution across key franchises, including Xywav (+18% YoY), Epidiolex (+15% YoY), and Zepzelca (+60% YoY).
• Positive momentum for rare oncology launches with Modeyso and Zepzelca.
• Xywav continues to show strong demand with significant new patient adds (425 net patient adds).
• Zanidatamab sBLA granted Priority Review by the FDA, with a PDUFA date set for August 25, 2026.
• Company reaffirms its full-year 2026 revenue and expense guidance.
• Generated $408 million in cash from operations in the first quarter.
• Agreement with Nippon Zoki to commercialize Epidyolex in Japan.

Negatives

• Xyrem net product sales decreased to $31.2 million from $37.2 million in the prior year.
• The company expects second-line use of Zepzelca to decline throughout the year.
• Cost of product sales increased in 1Q26 due to higher royalty expenses and increased inventory provisions.
• GAAP gross margin decreased slightly from 88.3% in 1Q25 to 87.5% in 1Q26.

Risks

• The time-consuming and uncertain regulatory approval process, including the risk that zanidatamab may not be approved in a timely manner or at all.
• The costly and time-consuming pharmaceutical product development process and the uncertainty of clinical success.
• Global economic, financial, and healthcare system disruptions and their potential negative impacts on business operations and financial results.
• Protecting and enhancing intellectual property rights and the risk that commercial success depends on obtaining, maintaining, and defending intellectual property protection and exclusivity.
• Delays or problems in the supply or manufacture of products and product candidates, including due to geopolitical tensions and military conflicts.
• Government investigations, legal proceedings, and other actions.
• The uncertainty of future tax, accounting, and other provisions and estimates.
• Fluctuations in the market price and trading volume of the company's ordinary shares.

Future Outlook

Jazz Pharmaceuticals reaffirms its full-year 2026 revenue guidance of $4.25 billion to $4.50 billion and expense guidance. The company anticipates the potential launch of zanidatamab in 1L HER2+ GEA later in 2026, following FDA approval.

Management Comments

• "Our first-quarter results reflect disciplined execution across the business, delivering 19% year-over-year growth alongside key pipeline advancements and positioning the company for an outstanding 2026," said Renee Gala, president and chief executive officer of Jazz Pharmaceuticals.
• "Demand for Xywav remained strong, our rare oncology launches with Modeyso and Zepzelca in 1LM ES-SCLC gained significant momentum, and Epidiolex continued to provide consistent growth."
• "Looking ahead, we are excited about the potential launch of zanidatamab in 1L GEA later this year, as we progress our pipeline and business development efforts to bring more life-changing therapies to patients and fuel durable long-term growth."

Industry Context

StockSavvy.ai notes that Jazz Pharmaceuticals' strong Q1 2026 performance, with 19% YoY revenue growth, aligns with a trend of established biopharma companies leveraging their existing portfolios while advancing promising pipeline candidates, particularly in oncology and rare diseases.

Comparison to Industry Standards

• Jazz Pharmaceuticals' 19% YoY revenue growth in Q1 2026 is significantly above the average growth rate for mid-to-large cap biopharmaceutical companies, which typically ranges from 5-10%.
• The 18% YoY growth for Xywav demonstrates strong market penetration and physician adoption, outperforming many established drugs in the sleep disorder market.
• The 60% YoY growth for Zepzelca in the oncology segment indicates successful market positioning and uptake, especially in the 1L ES-SCLC setting, which is a highly competitive therapeutic area.

Stakeholder Impact

• Shareholders: Positive impact due to strong revenue growth, reaffirmed guidance, and promising pipeline advancements, potentially leading to increased shareholder value.
• Patients: Continued access to and potential new therapies (zanidatamab) for serious conditions like GEA, epilepsy, and sleep disorders.
• Employees: Continued growth and investment in R&D and commercial operations may lead to job security and opportunities.
• Creditors: Strong cash flow generation ($408 million from operations) and reaffirmed guidance provide confidence in the company's ability to service its debt.

Next Steps

• Potential launch of zanidatamab in 1L HER2+ GEA following FDA approval.
• Second interim overall survival (OS) analysis for the HERIZON-GEA-01 trial expected mid-2026.
• Top-line readout from the Phase 3 ACTION trial of Modeyso expected late 2026 / early 2027.
• Progressing pipeline and business development efforts.
• Commercialize Epidyolex in Japan following completion of clinical trials and regulatory approval.

Key Dates

Recommendation

The company demonstrated robust top-line growth, strong execution across its product portfolio, and significant progress in its pipeline with a key FDA Priority Review for zanidatamab. Reaffirmed guidance and strong cash flow generation further support a positive outlook, making it an attractive investment.

Keywords

Jazz Pharmaceuticals, Q1 2026 Earnings, Revenue Growth, Zanidatamab, Xywav, Epidiolex, Zepzelca, FDA Priority Review